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Abstract
To confidently diagnose and treat Lyme disease, the clinician must first understand the
natural history of this disease, especially its protean early manifestations. Emergency
physicians, primary care physicians, and other providers need to be vigilant in terms of
the timely recognition of erythema migrans (EM), the unique marker of early localized
stage 1 disease. The classic EM, originally described as a slowly expanding bull's eye
lesion, is now recognized to be present in only the minority of cases (9%); the dominant
morphologic lesion of EM is now recognized to be the diffusely homogenous red plaque
or patch, which occurs in over 50% of cases. This update will define the current
morphologic features of early Lyme disease, the indication for serologic studies, and the
most recent treatment guidelines, including therapeutic pitfalls.

Introduction
This article focuses exclusively on the most recent diagnostic criteria and evidence-based
treatment of early Lyme disease (LD). The recognition of the early manifestations of LD
by Emergency and Primary Care Physicians, as well as other caregivers, is essential, as
this condition can progress to a multi-system disease if left untreated (1). One of the
reasons for misdiagnosis of early LD is a lack of understanding of the protean
morphologic features of erythema migrans (EM), the unique marker of early localized
stage 1 disease (2). Delaying the diagnosis of EM because the lesion does not conform to
a bull's eye and relying on serologic studies are often the main reasons why physicians
“miss the mark” in timely recognition of early LD. Likewise, antibiotic selection specific
for the treatment of this stage is crucial, or the disease can progress, as occurred in the
presented case (3).

Case Report
A 31-year-old woman presented to the Emergency Department in late spring for
evaluation of a slowly expanding, pruritic, burning circular red rash on the back of her
left leg. The rash was accompanied by a flu-like syndrome and temperature to 38.3°C
(101°F). She recalled that the rash occurred 1 week after hiking in a Pennsylvania State
Park. On physical examination, an 8-cm diffusely erythematous annular plaque was
found in the popliteal fossa (Figure 1). An ELISA (enzyme-linked immunosorbent assay)
titer for Lyme disease (LD) was negative. Because the lesion was not the “classic” bull's
eye configuration, the physician diagnosed cellulitis and prescribed a 10-day course of

cephalexin. One week later the patient returned for re-evaluation because the lesion had
enlarged to 12 cm and her flu-like syndrome persisted. Another physician was consulted
and recognized that the lesion was consistent with EM and represented early LD. A 10day course of doxycycline 100 mg b.i.d. (twice a day) was prescribed and the patient
improved without incident.

Figure 1. Case illustration, expanding EM in popliteal fossa.

Discussion
In the United States, the clinical manifestations of LD generally begin 7 to 10 days after
the bite of a deer tick (Ixodes scapularis or pacificus) infected with Borrelia burgdorferi.
Most infections with Borrelia burgdorferi are transmitted by the bite of a nymphal stage
Ixodes scapularis tick. These ticks are round, < 2 mm in size, and have four pairs of legs

(Figure 2). The epidemiologic setting is generally along the northeast corridor in the late
spring or early summer. The infected tick must be attached for at least 24–48 h and
transmits the disease in only 1–3% of bites (1). Stages of LD infection are typically
defined as early localized, early disseminated, and late chronic. EM is found in most
patients (60–80%) who develop the early localized form of LD (4). This annular,
erythematous lesion slowly expands to a maximal diameter of 16 cm. The lesions may be
asymptomatic, or cause burning, tenderness or pruritus, as in the above case. The rash
most often occurs at or near the site of the tick bite and, if untreated, persists for 2–3
weeks. Multiple EMs may occur in 17–50% of cases of early disseminated LD (5). The
latter represents hematogenous spread of the Borrelia burgdorferi and not the occurrence
of multiple tick bites.

Figure 2. Different stages of tick life cycle (note infectious nymph second from right).

The EM lesion has been classically described as erythematous with central clearing, the
so-named “bull's eye” appearance (Figure 3) (4). However, in a study of 118 cases of
EM, in which Borrelia burgdorferi infection was confirmed by culture or polymerase
chain reaction, the lesion was homogeneous in 59%, had central erythema in 32% (Figure
4), and was a “bull's eye” with central clearing in only 9% (2) (Table 1). The punctum
from the original tick bite is present 30% of the time (Figure 5) (2). EM also may present
as a vesicular lesion, as documented in 7–8% of patients (Figure 6) (2,6). A conclusion
that the “bull's eye” EM lesion actually represents a small minority of cases should
caution clinicians to be wary of the variety of “classic” presentations of EM.

Figure 3. “Classic” bull's eye EM, expanding erythema with central clearing (9%).

Figure 4. Diffuse homogeneous EM (50%), central redness (34%).
Table 1.
Morphologic Pattern of Erythema Migrans
Variable presentations

Percentage of patients (%)

Homogeneous

59

Central erythema

32

Punctum present

31

Central clearing, “bull's eye”

9

Vesicular or ulcerated

7

From Smith et al. (2).

Figure 5. Homogeneous EM, with central punctum (30%).

Figure 6. EM with vesicular reaction (9%).

Two-thirds of patients with untreated early LD are at risk of developing early
disseminated LD, characterized by musculoskeletal, cardiac, or neurologic features.
Cranial nerve palsies are the most common neurologic manifestation of early
disseminated LD, particularly in children. More than half of children with neurologic
symptoms have a facial palsy, which may be bilateral. The palsy can last from several
days to 2 months. An example of a patient who presented to the Emergency Department
for a Bell's palsy, subsequently determined to be secondary to LD, is seen in Figure 7.
The EM can persist in patients with facial palsy and should warrant careful physical
examination.

Figure 7. Bell's palsy.

Laboratory Testing

LD must be included in the differential diagnosis when encountering lesions with varying
characteristics, ranging from spreading erythematous to vesicular lesions. This includes,
but is certainly not limited to, insect stings, bites, drug eruptions, urticaria, contact
dermatitis, cellulitis, erythema multiforme, and patients presenting with other annular
lesions.
The most widely used studies for LD are antibody detection tests. These should be
reserved for confirmation of tentative clinical diagnoses that fall in the low to moderate
pre-test probability category (2, 7). If it is determined that testing is warranted, the
current recommendation from the Centers for Disease Control is for a two-step testing
process (8). The first step is to order an ELISA titer; this can be either a total Lyme, or
separate immunoglobulin G and immunoglobulin M. Only in the case of a positive
ELISA should the second step, confirmatory Western blot, be ordered (3). Antibody
testing in patients presenting with EM, as in our case, is not indicated because the rash
most often develops before the serologic conversion (3). Diagnosis in these cases should
be made based on clinical acumen. Laboratory testing for early LD should be reserved for
individuals from endemic areas with manifestations such as prolonged (> 2 weeks)
unexplained flu-like symptoms without EM (4).
Treatment
Treatment for LD should be tailored to the stage of disease and the age of the patient.
Patients with early acute or early disseminated LD should be treated with a 10- to 21-day
course of first-line antibiotics. The 21-day course is suggested for those who are
diagnosed later in the course of illness and with more severe systemic symptoms.
Doxycycline (100 mg b.i.d.) and amoxicillin (500 mg t.i.d.) have been proven efficacious
for the treatment of early LD (9-15). Amoxicillin is the treatment of choice in patients
under the age of 8 years. In cases of allergy or intolerance to these drugs, cefuroxime
axetil (500 mg b.i.d.) is a suitable substitute and also can be given to nursing mothers (915). Macrolides provide an alternative, but less effective, therapy for patients with allergy
or intolerance to the preferred regimens. Less than 10% of patients fail to respond to
antibiotic therapy with doxycycline, amoxicillin, or cefuroxime axetil (9-12). The
efficacy of doxycycline and amoxicillin are similar, and cefuroxime has been proven to
be as effective as doxycycline in treatment of patients with early localized Lyme disease
(9-12). It is important to note that the popular cephalosporin, cephalexin (Keflex), is not
effective in the treatment of LD, nor are any of the fluoroquinolone class (16, 17) (Table
2). Treatment is highly effective for LD and patients who complete the recommended
dose of antibiotics typically see complete resolution of symptoms.
Table 2.
Treatment of Early-Stage Lyme Disease (LD)
Drug
Doxycycline

Adult dosage

Pediatric dosage

100 mg p.o.

> 8 years; 1–2

Notes
Should not be used for children < 8 years

Drug

Adult dosage

Pediatric dosage

Notes

(Vibramycin, and
others)

b.i.d. × 10–21
days

mg/kg b.i.d. × 14–
21 days

Amoxicillin (Amoxil,
and others)

500 mg p.o.
t.i.d. × 14–21
days

25–50 mg/kg/d
divided t.i.d. × 14–
21 days

Cefuroxime axetil
(Ceftin)

500 mg p.o.
b.i.d. × 14–21
days

30 mg/kg/d divided
b.i.d. × 14–21 days

Azithromycin

500 mg p.o.
q.d. × 14 days

Clarithromycin

250 mg p.o. b.i.d. × 14 days

Erythromycin

Should be avoided. A less effective therapy, with some research indicating the
potential for microbial resistance.

Cephalexin (Keflex,
and others)

Not effective in the treatment of early LD, should be prescribed with caution
during the summer months for patients believed to have cellulitis in locations
where LD is endemic.

Fluroquinolones

Should be avoided, not effective in treatment of early LD.

old, or for pregnant or lactating women.

Okay for nursing mothers.
Alternative, but less effective, fourth-line
therapy for patients with allergies or
intolerance for preferred regimens.

p.o. = orally; b.i.d. = twice a day; t.i.d. = three times a day; q.d. = every day.
Data from Foy and Studdiford (3), Nowakowski et al. (16), and “Treatment of Lyme
disease” (17).
Should not exceed adult dosage.

Conclusions
In summary, although the incidence of Lyme disease is increasing, it remains an easily
treatable illness when diagnosed in the early stages. Clinical recognition of the variety of
“classic” skin lesions representing EM is essential in preventing the potentially
devastating long-term sequelae of untreated disease.
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